These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [25 years allogenic bone marrow transplantation in Basel: 1973-1998]. Passweg JR; Gratwohl A; Tichelli A; Hoffmann T; Nissen C; Kühne T; Favre G; Avoledo P; Cornu P; Herrmann R; Jeannet M; Osterwalder B; Sartorius J; Schifferli JA; Signer E; Stauffacher W; Speck B Schweiz Med Wochenschr; 1998 Oct; 128(42):1568-74. PubMed ID: 9824884 [No Abstract] [Full Text] [Related]
4. [Gene therapy of malignant hematologic diseases]. Porkka K Duodecim; 1998; 114(12):1275-85. PubMed ID: 11524774 [No Abstract] [Full Text] [Related]
5. Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning. Ganti AK; Lee SJ; Vose JM; Devetten MP; Bociek RG; Armitage JO; Bierman PJ; Maness LJ; Reed EC; Loberiza FR J Clin Oncol; 2007 Dec; 25(35):5643-8. PubMed ID: 18065735 [TBL] [Abstract][Full Text] [Related]
6. Hematopoietic stem cell transplantation: is ABO "a match made in heaven"? Szczepiorkowski ZM; Dumont LJ Transfusion; 2009 Apr; 49(4):612-4. PubMed ID: 19335373 [No Abstract] [Full Text] [Related]
7. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematologic malignancies in children. Huang X; Liu D; Liu K; Xu L; Chen H; Han W; Chen Y; Wang Y; Zhang X Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):91-4. PubMed ID: 19147085 [TBL] [Abstract][Full Text] [Related]
9. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687 [TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
11. Immune response gene polymorphisms in unrelated donor hematopoietic cell transplantation. Malkki M; Gooley T; Dubois V; Horowitz M; Petersdorf EW Tissue Antigens; 2007 Apr; 69 Suppl 1():50-3. PubMed ID: 17445163 [TBL] [Abstract][Full Text] [Related]
12. Comparative outcomes of reduced intensity and myeloablative allogeneic hematopoietic stem cell transplantation in patients under 50 with hematologic malignancies. Kim I; Yoon SS; Lee KH; Keam B; Kim TM; Kim JS; Kim HG; Oh MD; Han KS; Park MH; Park S; Kim BK Clin Transplant; 2006; 20(4):496-503. PubMed ID: 16842528 [TBL] [Abstract][Full Text] [Related]
13. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies. Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633 [TBL] [Abstract][Full Text] [Related]
14. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: Single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Parody R; Martino R; Sánchez F; Subirá M; Hidalgo A; Sierra J Am J Hematol; 2009 Sep; 84(9):571-8. PubMed ID: 19676118 [TBL] [Abstract][Full Text] [Related]
16. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Kim YR; Kim JS; Cheong JW; Song JW; Min YH Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689 [TBL] [Abstract][Full Text] [Related]
17. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013 [TBL] [Abstract][Full Text] [Related]
18. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951 [TBL] [Abstract][Full Text] [Related]
19. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies. Handgretinger R; Kurtzberg J; Egeler RM Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316 [TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell therapy for malignant diseases. Shapira MY; Hai AA; Tsirigotis P; Resnick IB; Or R; Slavin S Ann Med; 2007; 39(6):465-73. PubMed ID: 17852026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]